Axsome Therapeutics Files 8-K
Ticker: AXSM · Form: 8-K · Filed: Dec 31, 2025 · CIK: 1579428
Sentiment: neutral
Topics: corporate-filing, 8-K
Related Tickers: AXSM
TL;DR
AXSM filed an 8-K on 12/31/25, standard corporate update.
AI Summary
Axsome Therapeutics, Inc. filed an 8-K on December 31, 2025, reporting on other events and financial statements. The filing details the company's corporate information, including its principal executive offices at One World Trade Center, New York, NY, and its fiscal year end of December 31.
Why It Matters
This 8-K filing serves as an official record of Axsome Therapeutics' corporate status and financial reporting as of December 31, 2025.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not contain material non-public information that would typically impact stock price.
Key Players & Entities
- Axsome Therapeutics, Inc. (company) — Registrant
- December 31, 2025 (date) — Date of Report
- One World Trade Center, 29th Floor (location) — Principal Executive Offices
- New York, New York (location) — City, State of Principal Executive Offices
- 10007 (location) — Zip Code of Principal Executive Offices
FAQ
What is the exact date of the report for Axsome Therapeutics, Inc.'s 8-K filing?
The date of the report is December 31, 2025.
What is the principal executive office address for Axsome Therapeutics, Inc.?
The principal executive offices are located at One World Trade Center, 29th Floor, New York, New York, 10007.
What is the fiscal year end for Axsome Therapeutics, Inc.?
The fiscal year end for Axsome Therapeutics, Inc. is December 31.
What is the Commission File Number for Axsome Therapeutics, Inc.?
The Commission File Number for Axsome Therapeutics, Inc. is 001-37635.
What is the IRS Employer Identification Number (EIN) for Axsome Therapeutics, Inc.?
The IRS Employer Identification Number (EIN) for Axsome Therapeutics, Inc. is 45-4241907.
Filing Stats: 490 words · 2 min read · ~2 pages · Grade level 9.9 · Accepted 2025-12-31 07:10:24
Key Financial Figures
- $0.0001 — ch registered Common Stock, Par Value $0.0001 Per Share AXSM Nasdaq Global Market
Filing Documents
- axsm-20251231.htm (8-K) — 47KB
- axsm-ex99_1.htm (EX-99.1) — 26KB
- axsm-ex99_2.htm (EX-99.2) — 26KB
- img36028404_0.jpg (GRAPHIC) — 65KB
- img36951925_0.jpg (GRAPHIC) — 65KB
- 0001193125-25-337644.txt ( ) — 392KB
- axsm-20251231.xsd (EX-101.SCH) — 23KB
- axsm-20251231_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 31, 2025, Axsome Therapeutics, Inc. (the "Company") issued a press release announcing the U.S. Food and Drug Administration's acceptance and grant of Priority Review for its supplemental New Drug Application for the treatment of Alzheimer's Disease Agitation. Also on December 31, 2025, the Company issued a press release announcing that it had received formal pre-New Drug Application ("NDA") meeting minutes from the FDA for its planned NDA submission for AXS-12 in narcolepsy. The full text of each respective press release is filed as Exhibit 99.1 & Exhibit 99.2 hereto, and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 31, 2025. 99.2 Press Release dated December 31, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Axsome Therapeutics, Inc. Date: December 31, 2025 By: /s/ Herriot Tabuteau, M.D. Name: Title: Herriot Tabuteau, M.D. President and Chief Executive Officer